Mosquito-borne viral diseases are expanding their geographic reach, and chikungunya — long considered a pathogen of tropical and subtropical regions — is increasingly relevant to clinicians and travelers worldwide. Understanding its clinical trajectory matters because the debilitating joint pain that defines the disease can persist for months or years, affecting quality of life and productivity well beyond the acute phase.
Chikungunya virus, transmitted primarily by Aedes aegypti and Aedes albopictus mosquitoes, causes an acute febrile illness characterized by sudden-onset high fever and severe polyarthralgia. The JAMA Insights piece covers the full clinical arc: how the virus spreads, how to distinguish it from dengue and Zika — which share vector species and overlapping symptom profiles — the diagnostic workup including serology and PCR timing windows, and current management strategies, which remain largely supportive. Notably, the review addresses prevention, including the relatively recent regulatory milestone of an approved vaccine (IXCHIQ, a live-attenuated single-dose vaccine authorized in the U.S. in 2023) for adults at increased risk.
This clinical synopsis arrives at a meaningful moment. Aedes albopictus has established populations in parts of Europe and North America, raising the realistic prospect of autochthonous transmission beyond historically endemic zones. The 2023–2024 outbreak surge in the Americas underscores that chikungunya is no longer a niche travel-medicine concern. For health-conscious adults, the post-acute rheumatic syndrome — affecting an estimated 30–40% of patients — is the most consequential dimension, as it can mimic inflammatory arthritis and lead to prolonged disability. The availability of a vaccine changes the risk calculus for travelers and residents in affected regions, though real-world immunogenicity data in diverse populations are still accumulating. This overview is clinically useful but represents established consensus rather than novel research.